Definitive Healthcare's 2026 guidance assumes a modest 2-point net dollar retention (NDR) improvement following a bottoming in 2025, driven by data remediation and AI innovation. The NDR recovery is expected to gradually accelerate throughout 2026, supported by new product rollouts and integration strategies.
Generated by Dafinchi AI. Source-grounded AI analysis, not investment advice.
Can you quantify the 'couple of points' NDR improvement assumed in the 2026 guide and the timeline for that inflection?
Definitive Healthcare Corp. (DH) has explicitly indicated in its 2025 Q4 earnings call that the net dollar retention (NDR) metric is expected to bottom out in 2025, with an improvement anticipated through 2026. Here is a detailed quantification and timing of that NDR improvement based on management commentary and guidance:
Magnitude: The company refers to the assumed improvement as a "couple of points" increase in NDR for 2026 relative to the trough in 2025. CFO Casey Heller quantified this as a modest improvement, specifically a couple of points on a net dollar retention basis baked into the 2026 guidance. The management is confident in delivering this incremental improvement but remains cautious about potential for even better performance as the year progresses 12.
Context: The NDR decline in 2025 was primarily driven by upsell pressures stemming from prior claims data disruptions. These disruptions caused a shortfall in record volumes (approximately 30% less in some areas) which affected customer renewals, cross-sell, and upsell opportunities 31. Now that claims data issues are remediated—with volumes restored to or above historical levels—and product innovations including AI enhancements are ramping up, management expects a rebound in NDR.
Bottoming in 2025: Management views 2025 as the bottom-year for NDR, indicating no further meaningful declines expected beyond this point. Gross dollar retention already improved by about 200 basis points in 2025, signaling stabilization 42.
Improvement During 2026: The guidance assumes:
Gradual Improvement: The company expects the improvement trajectory to build throughout the year as the benefit of innovation, data remediation, and integration strategies fully manifest in customer renewals and expansions 8. They describe a "modest uptick in the second half relative to the first half" of 2026 revenue, consistent with gradual NDR improvement 910.
Claims Data Remediation Completed: Claims data volumes have been restored to above historical levels, impacting renewal and upsell positively 3111.
Product Innovation and AI: The rollout of Gen AI-enabled products starting in Q2 2026 is expected to unlock new use cases, improving customer value and thus retention and expansion 478.
Integration Strategy: Increasing integrations with customers’ systems (60 new integrated customers added in Q4 2025, 160 for full year) improve stickiness and renewal rates, which support NDR recovery 121314.
Value-Based Pricing Model: This model supports upsells and cross-sells as more users get access to the platform through AI-enhanced tools, further lifting NDR 412.
| Aspect | Detail | Citation(s) |
|---|---|---|
| Assumed NDR improvement | "A couple of points" (modest 2-point+ improvement) on net dollar retention in 2026 | 12 |
| NDR bottom year | 2025 | 4215 |
| Timeline for inflection | Improvement starts in 2026; ramp-up into Q2 and second half of 2026 | 591067 |
| Drivers | Claims data restoration, AI product launches (Q2+), increased integrations, value pricing | 43121137148 |
| Renewal cycle impact | Fall 2025 product upgrades mostly impact 2026 renewals, especially Q1 and Q2 | 51 |
| Revenue guidance context | Modest uptick in 2H 2026 revenue reflecting improving NDR and renewals | 910 |
Definitive Healthcare's 2026 guidance explicitly assumes a modest NDR improvement of approximately 2 percentage points relative to its 2025 trough, with the bottoming of NDR expected in 2025. The improvement is anticipated to materialize gradually over 2026, supported by completed claims data remediation, a series of AI-powered product innovations primarily launching in Q2, and enhanced customer integration strategies that increase renewal quality. The company's approach and data as discussed provides a reasonable quantifiable target and timeline for modeling NDR recovery and associated revenue stabilization or growth in 2026.
Disclaimer: The output generated by dafinchi.ai, a Large Language Model (LLM), may contain inaccuracies or "hallucinations." Users should independently verify the accuracy of any mathematical calculations, numerical data, and associated units, as well as the credibility of any sources cited. The developers and providers of dafinchi.ai cannot be held liable for any inaccuracies or decisions made based on the LLM's output.
Marvell attributes near-term data center margin pressure to the expanding mix of custom silicon, with management emphasizing that revenue levels and product mix drive gross margins each quarter. While the Q3 headwind is primarily a mix effect, management expects margins to stabilize as the custom ramp accelerates in H2 and broad-based growth supports margin expansion into fiscal 2028.
Sources used
Research questionWhat did management say about Data center margin drivers from custom mix?
Answer outline
Investors should read management’s “2H acceleration” as a qualitative uptick in the second half versus the first half, supported by guidance for sequential back-half growth and a Helios ramp that becomes more impactful in Q4. The Q2 107% YoY growth establishes the first-half baseline, with Q3 and Q4 expected to exceed it through supply and product timing.
Sources used
Research questionHow should investors interpret management’s view that data center AI growth will “accelerate” in the second half versus the first half, given Q2’s 107% year-over-year growth and the Q3/Q4 guidance trajectory?
Answer outline
Western Digital outlines a dual-path outlook: LTA pricing remains contract-driven and predictable, particularly for nearline pricing, while offering upside in non-nearline contracts, and the exabyte growth trajectory remains robust at 25% plus, supported by 40TB ePMR ramp and upcoming HAMR and higher-capacity drives, with visibility extending through 2029–2031. Quarterly margins may vary due to LTA timing, but the long-term demand signal remains strong.
Sources used
Research questionWhat did management say about LTA pricing and exabyte growth outlook?
Answer outline
Pfizer's update highlights a $1.5 billion year-to-date non-COVID uplift driven by Eliquis alongside other products like NURTEC and Padcev, though the exact split isn’t quantified. Eliquis is projected to grow 20%–25% this year, while Padcev shows an initial acceleration that should moderate as la/mUC penetration matures, with upside potential from MIBC over time.
Sources used
Research questionWithin the $1.5 billion year-to-date increase in non-COVID revenue guidance, how much is due to Eliquis versus other products, and what is the updated Eliquis growth outlook? Also, with Padcev's expanded label, what is the expected growth path for that asset going forward?
Answer outline
Match Group's Q2 2026 earnings discussion centers on a consistent MAU-payer trend correlation, where payer declines run smaller than MAU declines and payer penetration rose year over year. Management notes MAU momentum drives direct revenue per MAU and payer trends over time, but warns quarterly movements can diverge due to product and monetization initiatives, while maintaining a positive long-term outlook and guidance for payer declines to ease in H2.
Sources used
Research questionWhat did management say about MAU and payer trend correlation?
Answer outline
IFF's Scent segment posted an 8% Q2 sales rise led by double-digit growth in Fragrance Ingredients and a resilient Consumer Fragrance line, even as Fine Fragrance faced Middle East volatility. The firm outlines a two-track H2: mid-single-digit growth for Fine Fragrance with a Q3 soft patch and a rebound in Q4, while Consumer Fragrance normalizes after a standout Q2, underpinned by an R&D-driven push into 2027.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF's Scent recovery is advancing on multiple fronts, led by volume-driven growth, a re-energized R&D pipeline, and stable management of regional volatility. In 2H, Fine Fragrance should soften in Q3 and rebound in Q4, while Consumer Fragrance normalizes to a low single-digit pace, with 2027 R&D investments positioned to bolster long-term competitive strength.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
Management ties the Scent recovery to a significantly stronger R&D pipeline and execution, with Scent sales up 8% and EBITDA up 5% driven by volume gains and productivity. For 2H, Fine Fragrance is expected to be soft in Q3 but stronger in Q4, while Consumer Fragrance should normalize to low-single-digit growth; the 2027 plan emphasizes sustained R&D investment, perfumer-led innovation, and a shift toward higher-value natural ingredients.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF's Scent recovery is led by Fragrance Ingredients and volume gains, with Fine Fragrance expected to be softer in Q3 and rebound in Q4. The company emphasizes a rebuilt R&D pipeline and higher-value product shifts to support competitive positioning into 2027.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF outlines a Scent recovery driven by a strengthened R&D pipeline, improved go-to-market execution, and a strategy to lift market share across Fine and Consumer Fragrance. The company anticipates a softer Q3 but a stronger Q4 for Fine Fragrance and a normalization to low single-digit growth for Consumer Fragrance in H2, supported by an 8-9% of sales R&D investment through 2027.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF Scent’s recovery hinges on a rebuilt R&D engine and market-share gains in Consumer Fragrance, with Fine Fragrance stabilizing amid Middle East volatility and Fragrance Ingredients normalization. In H2, Fine Fragrance is expected to soften in Q3 and strengthen in Q4, while Consumer Fragrance normalizes to low single-digit growth; management also emphasizes sustaining R&D investment around 8-9% of sales to support 2027 competitiveness.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF outlines a Scent recovery driven by Fragrance Ingredients momentum and a robust R&D build, with Fine Fragrance softening in Q3 and strengthening in Q4, while Consumer Fragrance stabilizes through renewed R&D and go-to-market execution ahead of 2027.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
Dafinchi